Mandate

Vinge advises AstraZeneca on the sale of a pharmaceutical portfolio

June 04, 2007

Vinge is advising AstraZeneca on the sale of a large number of pharmaceuticals to Recip AB. The sale includes a portfolio of infection drugs for sale in Sweden, Norway, Denmark and Iceland. The annual sales of the 17 drugs included in the portfolio are SEK 240 million.

AstraZeneca is represented by partner Malin Leffler, assisted by Anna Berntsson and Claes Henriksson.

The REPowerEU Plan – The EU Commission’s response to the energy market disruptions

On 18 May 2022, the EU Commission presented the REPowerEU Plan in response to the current world-wide energy market disruptions which have been caused by Russia’s invasion of Ukraine.
May 24, 2022

Sanctions update April 14

Further to our previous sanctions updates Sanctions update March 16, Sanctions Newsletter update 11 of March, Sanctions newsletter of 3 of March, Sanctions newsletter of 25 of February, we herewith provide a further update of recent sanctions developments following Russia’s war against Ukraine:
April 14, 2022

New guidance on sustainability agreements between competitors

On 1 March 2022, the European Commission published draft revised guidelines on co-operation between competitors, together with draft revised block exemption regulations for specialisation agreements and R&D agreements. Unlike the current guidelines, which expire on 31 December 2022, the new guidelines include a chapter on the assessment of so-called sustainability agreements.
April 01, 2022